Curative surgery for gastric cancer in a patient with an implantable left ventricular assist device.
Yuki NakamuraKoichi TodaTeruya NakamuraShigeru MiyagawaYasushi YoshikawaSatsuki FukushimaShunsuke SaitoDaisuke YoshiokaKeitaro DomaeTsuyoshi TakahashiTadayoshi HashimotoYuichiro DokiYoshiki SawaPublished in: Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs (2017)
The number of patients with end-stage heart failure treated by a left ventricular assist device (LVAD) is dramatically increasing, because the LVAD has been widely accepted for its clinical results. According to the initiation of destination therapy, the prevalence of malignancy in patients with an LVAD is estimated to increase. In patients with LVADs, abdominal surgery for visceral malignancy is associated with technical difficulties because of the presence of an LVAD pump or the driveline which is located transversely in the preperitoneal space. Herein, we describe the technical management for complete resection of gastric cancer in a patient with an LVAD.
Keyphrases
- left ventricular assist device
- heart failure
- case report
- minimally invasive
- risk factors
- stem cells
- coronary artery bypass
- left ventricular
- insulin resistance
- type diabetes
- atrial fibrillation
- adipose tissue
- rectal cancer
- acute coronary syndrome
- newly diagnosed
- prognostic factors
- percutaneous coronary intervention
- cell therapy